Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
van der Wall SJ, van Rein N, van den Bemt B, Kruip MJHA, Meijer K, Te Boome LCJ, Simmers TA, Alings AMW, Tieleman R, Klok FA, Huisman MV, Westerweel PE.
van der Wall SJ, et al. Among authors: kruip mjha.
Europace. 2019 Mar 1;21(3):414-420. doi: 10.1093/europace/euy220.
Europace. 2019.
PMID: 30339226